Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Crescendo
- Development stage
- Unknown
- Lead developer
- Valeos Pharma
- Administration
- Inhalation
01
Overview
**Crescendo** is Valeos Pharma's cultivar 02: an EU-GMP-certified medicinal cannabis flower product. It is a multicomponent botanical preparation whose pharmacological activity is expected to arise from plant-derived cannabinoids and terpenes acting on the endocannabinoid system; Valeos has not publicly disclosed a cultivar-specific standardized cannabinoid composition, clinical indication, or target profile for this portfolio item. ([valeos.dk](https://www.valeos.dk/portfolio))
- Other names
- Crescendo
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Crescendo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crescendo.